What's New in the Evolving Management of Type 2
Diabetes: Individualizing Therapy with
Novel Treatment Options

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 10, 2018 to January 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grant from
Boehringer Ingelheim and Lilly USA Alliance

Description:
The American Diabetes Association (ADA) estimates that more than 25.8 million people in the United States have diabetes and that 1 in 3 Americans born in 2017 will develop diabetes at some point of their life. Approximately 90-95% of adults have type 2 Diabetes Mellitus (T2DM) and the Centers for Disease Control (CDC) estimates that uncontrolled type T2DM doubles a person’s risk for death, and on average a loss of 10-15 years of life. The management of type T2DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. The price tag associated with treatment of type T2DM increases with disease severity, as more dollars are spent managing the significant comorbidities associated with advanced disease. Moreover, it is estimated that diabetes patients, on average, have medical expenditures that are approximately 2.3 times higher relative to the absence of diabetes. Fortunately, recent advances in treatments have given healthcare professionals the ability to shrink the clinical practice gap and implement therapeutic strategies to effectively treat this disease. Incorporating an individualized regimen for patients, to include education, lifestyle change, mono and combination therapy of GLP-1 agonists, insulins and SGLT-2 inhibitors, will help overcome the barriers associated with T2DM.

Upon Completion of this activity, participants will be able to:

  • Summarize recent clinical data regarding the role of newer antidiabetic therapies in reducing macrovascular risk factors associated with T2DM, including hypertension and heart failure

  • Understand the roles of newer GLP-1 agonists, insulins and SGLT-2 inhibitors in the type 2 diabetes treatment paradigm

  • Examine recent clinical data related to the combination of basal insulin and GLP-1 therapies and their role in the type 2 diabetes treatment paradigm
     

Faculty: Carol H. Wysham, MD,
Clinical Professor of Medicine
University of Washington, Spokane
Section Head
Rockwood Center for Diabetes and Endocrinology

Disclosure:

Dr. Wysham acts as an advisor or consultant for Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Eli Lilly, Janssen Pharmaceuticals, Novo Nordisk, and Sanofi. She also serves as a speaker or a member of a speaker’s bureau for AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Insulet Corporation, Eli Lilly, Janssen Pharmaceuticals, Novo Nordisk, and Sanofi. Her presentation has been peer reviewed for any bias.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Boehringer Ingelheim and Lilly USA Alliance

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue